PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy

Gu, Guangzhi; Xia, Huimin; Hu, Quanyin; Liu, Zhongyang; Jiang, Mengyin; Kang, Ting; Miao, Deyu; Tu, Yifan; Pang, Zhiqing; Song, Qing; Yao, Lei; Chen, Hongzhan; Gao, Xiaoling; Chen, Jun

doi:10.1016/j.biomaterials.2012.09.044

Cited by 165 publications

(108 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In recent in vitro or in vivo studies, they were used for the delivery of cytostatic drugs [57][58][59][60], cytotoxic peptides [61], antibodies [62,63], siRNA [64] or even oncolytic viruses [65], to deliver irradiation [66] or to improve imaging techniques [67]. The frame of this paper does not allow to discuss these new therapeutic opportunities in detail.…”

Section: Other Approachesmentioning

confidence: 99%

Glioblastomas: are individual therapies required for individual tumors?

Classen¹

2013

J Cancer Ther Res

View full text Add to dashboard Cite

Section: Other Approachesmentioning

confidence: 99%

Glioblastomas: are individual therapies required for individual tumors?

Classen¹

2013

J Cancer Ther Res

View full text Add to dashboard Cite

“…Many endocytic inhibitors have been used to characterize the endocytosis pathway involved in nanoparticles. [38][39][40][41][42] In the present study, we selected chlorpromazine, amiloride, filipin, and M-β-CD as endocytic inhibitors to investigate the endocytosis pathway of iRGD-modified SSLs. Also, 4°C was selected to investigate the impact of energy on cellular uptake.…”

Section: Time (Days)mentioning

confidence: 99%

Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid–paclitaxel (CLA-PTX) on B16-F10 melanoma

Zhong

Zhang

et al. 2014

IJN

View full text Add to dashboard Cite

In the present study, we prepared a novel delivery system of iRGD (CRGDK/RGPD/EC)-modified sterically stabilized liposomes (SSLs) containing conjugated linoleic acid–paclitaxel (CLA-PTX). The anti-tumor effect of iRGD-SSL-CLA-PTX was investigated on B16-F10 melanoma in vitro and in vivo. The in vitro targeting effect of iRGD-modified SSLs was investigated in a real-time confocal microscopic analysis experiment. An endocytosis-inhibition assay was used to evaluate the endocytosis pathways of the iRGD-modified SSLs. In addition, the in vitro cellular uptake and in vitro cytotoxicity of iRGD-SSL-CLA-PTX were evaluated in B16-F10 melanoma cells. In vivo biodistribution and in vivo antitumor effects of iRGD-SSL-CLA-PTX were investigated in B16-F10 tumor-bearing mice. The induction of apoptosis by iRGD-SSL-CLA-PTX was evaluated in tumor-tissue sections. Real-time confocal microscopic analysis results indicated that the iRGD-modified SSLs internalized into B16-F10 cells faster than SSLs. The identified endocytosis pathway of iRGD-modified SSLs indicated that energy- and lipid raft-mediated endocytosis played a key role in the liposomes’ cellular uptake. The results of the cellular uptake experiment indicated that the increased cellular uptake of CLA-PTX in the iRGD-SSL-CLA-PTX-treated group was 1.9-, 2.4-, or 2.1-fold compared with that in the CLA-PTX group after a 2-, 4-, or 6-hour incubation, respectively. In the biodistribution test, the CLA-PTX level in tumor tissues from iRGD-SSL-CLA-PTX-treated mice at 1 hour (1.84±0.17 μg/g) and 4 hours (1.17±0.28 μg/g) was 2.3- and 2.0-fold higher than that of CLA-PTX solution at 1 hour (0.79±0.06 μg/g) and 4 hours (0.58±0.04 μg/g). The value of the area under the curve for the first 24 hours in the tumors of iRGD-SSL-CLA-PTX-treated mice was significantly higher than that in the SSL-CLA-PTX and CLA-PTX solution-treated groups ( P <0.01). The in vivo antitumor results indicated that iRGD-SSL-CLA-PTX significantly inhibited the growth of B16-F10 tumors compared with the SSL-CLA-PTX or CLA-PTX solution-treatment groups ( P <0.01). The results of tumor-cell apoptosis showed that tumors from the iRGD-SSL-CLA-PTX-treated group exhibited more advanced cell apoptosis compared with the control, CLA-PTX solution-, and SSL-CLA-PTX-treated groups. In conclusion, the antitumor effect of iRGD-SSL-CLA-PTX was confirmed on B16-F10 melanoma in vitro and in vivo.

show abstract

“…8 These reports are in contrast, however, to others, which suggest that the attachment of tumor-targeting antibody on NPs enhances total accumulation in solid tumor. [9][10][11] One difference might be the presence or absence of polyethylene glycol (PEG) in the complex and its impact on the EPR effect. 12 In fact, the increased circulation time…”

Section: Introductionmentioning

confidence: 99%

“…In light of this, a significant number of tumor-targeting studies have focused on the evaluation of parameters affecting the EPR effect, 13,14 and additional studies are clearly needed to understand the influence of NPs' modification on tumor localization and uptake. 3,7,[9][10][11] Currently, several nanotechnology-enabled diagnostic and therapeutic agents for cancer are in clinical trials. 15 Indeed, multifunctionality is the key feature of NP-based agents.…”

mentioning

confidence: 99%

Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies

Capolla¹,

Garrovo²,

Zorzet³

et al. 2015

IJN

View full text Add to dashboard Cite

The expectations of nanoparticle (NP)-based targeted drug delivery systems in cancer, when compared with convectional therapeutic methods, are greater efficacy and reduced drug side effects due to specific cellular-level interactions. However, there are conficting literature reports on enhanced tumor accumulation of targeted NPs, which is essential for translating their applications as improved drug-delivery systems and contrast agents in cancer imaging. In this study, we characterized biodegradable NPs conjugated with an anti-CD20 antibody for in vivo imaging and drug delivery onto tumor cells. NPs’ binding specificity mediated by anti-CD20 antibody was evaluated on MEC1 cells and chronic lymphocytic leukemia patients’ cells. The whole-body distribution of untargeted NPs and anti-CD20 NPs were compared by time-domain optical imaging in a localized human/mouse model of B-cell malignancy. These studies provided evidence that NPs’ functionalization by an anti-CD20 antibody improves tumor pharmacoki-netic profiles in vivo after systemic administration and increases in vivo imaging of tumor mass compared to non-targeted NPs. Together, drug delivery and imaging probe represents a promising theranostics tool for targeting B-cell malignancies

show abstract

PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy

Cited by 165 publications

References 51 publications

Glioblastomas: are individual therapies required for individual tumors?

Glioblastomas: are individual therapies required for individual tumors?

Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid–paclitaxel (CLA-PTX) on B16-F10 melanoma

Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies

Contact Info

Product

Resources

About

PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy

Cited by 165 publications

References 51 publications

Glioblastomas: are individual therapies required for individual tumors?

Glioblastomas: are individual therapies required for individual tumors?

Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid&ndash;paclitaxel (CLA-PTX) on B16-F10 melanoma

Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies

Contact Info

Product

Resources

About

Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid–paclitaxel (CLA-PTX) on B16-F10 melanoma